Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.21.1
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2021
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]      
Total revenue   $ 15,633 $ 13,261
Seagen      
Disaggregation of Revenue [Line Items]      
Total revenue   366 448
AstraZeneca      
Disaggregation of Revenue [Line Items]      
Total revenue $ 13,000 14,500 2,711
Servier      
Disaggregation of Revenue [Line Items]      
Total revenue   $ 767 $ 10,102